PIK3CA and breast cancer: The TP53–PIK3CA contrast provides a clinically relevant and mechanistically distinct testbed: both genes are frequent drivers in BC, associated with divergent transcriptomic programs and prognostic implications across the Cancer Genome Atlas and independent cohorts.